Kintsugi(US) | $6,000,000 | (May 31, 2024)
Valar Labs | $22,000,000 | (May 31, 2024)
Plural Energy | $2,330,000 | (May 31, 2024)
Gedea Biotech AB
Sweden
- Lund, Skane
- 26/05/2023
- Unknown
- $1,395,000
Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Standard treatment consists of antimicrobials, but recurrence rate is15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health in 2021
and research into novel non-antimicrobial based treatments is timely.
- Industry Biotechnology Research
- Website https://gedeabiotech.com/
- LinkedIn https://www.linkedin.com/company/gedeabiotech/
Related People
Annette SäfholmFounder
Sweden -
Lund, Kalmar County,
Has extensive project manager- and business development experience from both non-public, public start-ups and established companies, as well as from health care sector. Co-founder of WntResearch AB. and holds a PhD in medicine from Lund University and M.Sc. in Medical Biology from Linköping University.
Specialties: I have ten years experience within project managment, business development and communications within medicine/Life Sciences. Special scientific focus on women's health, oncology, microbiology, hematology and immunology.
HoundDog.ai | $3,100,000 | (May 31, 2024)
Fortunafi | $9,500,000 | (May 31, 2024)
Faircado | $3,252,930 | (May 31, 2024)
Basalt Tech | $3,500,000 | (May 31, 2024)
FintechOS | $60,000,000 | (May 31, 2024)
Remark | $10,300,000 | (May 31, 2024)
Revive | $3,500,000 | (May 31, 2024)
Viable(UK) | $3,100,000 | (May 31, 2024)
Weave | $10,000,000 | (May 31, 2024)